Adverse Event Reporting in Psoriasis Trials, 2020-2025

187 randomized controlled trials for psoriasis published between 2020 and 2025 were analyzed for adverse event reporting completeness. The median Adverse Event Reporting Completeness Index (AERCI-Core) score was 6.00, indicating suboptimal overall reporting quality, with only 26.2% of studies rated as high quality. This cross-sectional meta-epidemiological study by Zhaoxin Yang, shared under a CC-BY-4.0 license, identifies factors associated with reporting quality.

Use Cases

• Analyze factors influencing adverse event reporting completeness based on journal impact factor and psoriasis subtype
• Benchmark reporting quality against CONSORT-Harms 2022 recommendations based on the AERCI score
• Identify common gaps in adverse event documentation based on low adherence rates for items like AE management and timing
• Study temporal trends in safety data reporting for psoriasis therapies based on trials from 2020-2025

Strengths

• Analysis of 187 randomized controlled trials provides a substantial sample for meta-epidemiological study
• Includes specific quality metrics like the median AERCI-Core score of 6.00 and the 26.2% high-quality rate
• Identifies statistically significant predictors of reporting completeness (journal impact factor, pustular psoriasis subtype)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect publication bias inherent to the PubMed and Cochrane Database sources

Provenance

Source

figshare

Collection Method

Comprehensive search of PubMed and the Cochrane Database for RCTs meeting eligibility criteria

Time Range

2020 to 2025

Freshness

Last updated 2026-03-18 07:46:06

Geography

null